Recent studies have highlighted the role of kidney-acting drugs, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists, in the management of AF and heart failure. This evidence concerns the gene NR3C2 and heart failure.